Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 63

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 63
---
 for any failure by the Company to comply with the terms of this Agreement. The
Company and Investor each acknowledge that a breach by either of it of its respective obligations hereunder will cause irreparable harm
to the Company or Investor, as applicable, and that the remedy at law for any such breach may be inadequate. The Company and Investor
each therefore agree that, in the event of any such breach or threatened breach by the other party, the Company, on the one hand, and
the Investor, on the other hand, shall be entitled, in addition to all other available remedies, to an injunction restraining any breach,
without the necessity of showing economic loss and without any bond or other security being required, this being in addition to any other
remedy to which either party may be entitled by law or equity.

(n) . In the event that (i) any action for enforcement of this Agreement is commenced or is enforced by the Investor through any
legal proceeding; (ii) an attorney is retained to represent the Investor in any bankruptcy, reorganization, receivership or other proceedings
affecting creditors’ rights and involving a claim under this Agreement; or (iii) subject to hereof, an attorney
is retained to represent the Investor in any other proceedings whatsoever in connection with this Agreement, then the Company shall pay
to the Investor, as incurred by the Investor, all reasonable costs and expenses including reasonable attorneys’ fees incurred in
connection therewith, in addition to all other amounts due hereunder.

(o) . No provision of this Agreement may be amended other than by a written instrument signed
by both parties hereto and no provision of this Agreement may be waived other than in a written instrument signed by the party against
whom enforcement of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate
as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise
thereof or of any other right, power or privilege.

<div align='center'>** Signature Page Follows **</div>

| -35- |

IN WITNESS WHEREOF,
the Investor and the Company have caused this Agreement to be duly executed as of the Execution Date.

| THE COMPANY:                |                     |
| Biodexa Pharmaceuticals     
 Plc                         |                     |
| By:                         | /s/ Stephen Stamp   |
| Name:                       | Stephen Stamp       |
| Title:                      | President and